Subject(s)
Exanthema , Failure to Thrive , Exanthema/diagnosis , Exanthema/etiology , Failure to Thrive/diagnosis , Failure to Thrive/etiology , Humans , Infant , Weight LossABSTRACT
Up to 1.3 million children from the former Soviet Union (fSU) and Eastern Europe have been placed in institutional care worldwide. With the hope of ensuring the child's health in the immediate post-adoption period, these children are known to receive many injections of vaccines, vitamins, and medications, many unnecessary and often administered with unsafe technique. This practice can lead to formation of suppurative granulomas in these children. Though rare, dermatologists should be aware of these conditions in adoptees from Eastern Europe.
Subject(s)
Abscess/drug therapy , Abscess/etiology , Granuloma/etiology , Skin Diseases/drug therapy , Skin Diseases/etiology , Abscess/physiopathology , Child, Adopted/statistics & numerical data , Clarithromycin/therapeutic use , Europe, Eastern , Female , Granuloma/drug therapy , Granuloma/physiopathology , Humans , Infant , Injections, Intramuscular/adverse effects , Rifampin/therapeutic use , Risk Assessment , Russia , Skin Diseases/physiopathology , USSRABSTRACT
Neurofibromatosis type 1 is a genetic disorder characterized by variable phenotypic manifestations. The diagnostic criteria, 25 established in 1987, are broad to encompass these pleiotropic findings. Included are the specific osseous manifestations of 26 sphenoid dysplasia and dysplasia or thinning of the cortex of long bones. This review highlights recent evidence on the role of 27 neurofibromin in bone development and suggests consideration for additional diagnostic criteria.
Subject(s)
Cafe-au-Lait Spots/diagnosis , Neurofibromatosis 1/diagnosis , Polydactyly/diagnosis , Skin Neoplasms/diagnosis , Adult , Cafe-au-Lait Spots/complications , Humans , Male , Neurofibromatosis 1/complications , Polydactyly/complications , Skin Neoplasms/complicationsABSTRACT
Dovitinib (TKI258) is a multi-targeted receptor tyrosine kinase inhibitor currently under clinical trials for a wide variety of cancers. Well-known side effects include nausea, vomiting, diarrhea, and fatigue. To date, there have only been only two reported cases with skin manifestations as a side effect. We report a case of eruptive facial milia and comedones in the setting of dovitinib treatment for metastatic gastrointestinal cancer. This case is unique as the clinical presentation was more rapid in onset and showed an absence of inflammatory lesions. Although the pathogenesis for skin manifestations is presently unknown, we present this case to increase awareness of potentially under-reported cutaneous side effects.
